Page last updated: 2024-10-27

fluorouracil and Adenocarcinoma Of Kidney

fluorouracil has been researched along with Adenocarcinoma Of Kidney in 212 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
" Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment."7.81Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015)
" Two weeks after, she received her first cycle of cyclophosphamide, methotrexate, and 5FU (CMF) as a part of her breast cancer treatment."3.81Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer. ( Al-Hameed, FM, 2015)
" Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma."3.71gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001)
"We found eight patients with renal cell carcinoma who developed carpal tunnel syndrome (CTS) during treatment with IL-2, fluorouracil (5-FU), and alpha-interferon (alpha-IFN)."3.69Carpal tunnel syndrome associated with interleukin-2 therapy. ( Austin, SG; Forman, AD; Puduvalli, VK; Sella, A, 1996)
"Capecitabine has clinical activity in MRCC patients who have non-clear cell histology and a good or intermediate prognosis."2.77Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma. ( Demidov, L; Galchenko, V; Kharkevich, G; Naidzionak, U; Petenko, N; Sinelnikov, I; Tsimafeyeu, I, 2012)
"We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy."2.77Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. ( Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J, 2012)
"The combination of sorafenib plus gemcitabine and capecitabine is tolerable, but requires attenuation of sorafenib and capecitabine dosing because of the overlapping toxicity of hand-foot syndrome."2.76A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981. ( Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ, 2011)
"Capecitabine was administered 2,000 mg/m(2) daily for 14 days followed by 1 week rest."2.75A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer. ( Kellokumpu-Lehtinen, PL; Koskinen, S; Sunela, KL, 2010)
"In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents."2.75Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. ( Aitchison, M; Gore, ME; Griffin, CL; Hancock, B; Hussain, T; James, N; Mardiak, J; Mulders, PF; Oliver, RT; Parmar, MK; Patel, PM; Pyle, L; Royston, P; Sylvester, R, 2010)
"The highly vascular nature of renal carcinoma cells suggests that inhibition of angiogenesis may be beneficial in this disease."2.74Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. ( Brossart, P; Gorschlüter, M; Hauser, S; Kim, Y; Kraemer, A; Müller, SC; Schmidt-Wolf, IG, 2009)
"Fifty-five (55) patients with renal cell cancer were randomly divided into a Haishengsu group (n = 27, 2."2.74Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial. ( Chen, SG; Li, GY; Liu, JZ; Wang, CB; Wang, LX; Zhang, B; Zhao, XW, 2009)
"Metastatic renal carcinoma patients without prior fluoropyrimidine therapy and normal organ function were treated with oral capecitabine 880 mg/m(2) twice daily along with continuous infusion GTI-2040 starting at 148 mg/m(2)/day for 21 days, for each 28-day cycle."2.73A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. ( Bukowski, R; Desai, AA; Kardinal, CG; Lewis, N; Makalinao, A; Murray, P; Poiesz, B; Quinn, DI; Stadler, WM; Torti, FM, 2008)
"Capecitabine as third-line treatment showed a favourable toxicity profile, but exhibited low activity in patients with advanced renal cell carcinoma after failing immunotherapy."2.73Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy. ( Barbanti, G; de Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Paolelli, L; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A, 2007)
"Gemcitabine was given by intravenous administration over 30 min on day 1, week 1 and day 8, week 2."2.73A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma. ( Amato, RJ; Khan, M, 2008)
"Sixty-two patients with metastatic renal cell carcinoma participated in a Phase II study."2.73Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel. ( Best, LA; Gaitini, D; Gez, E; Kuten, A; Mashiach, T; Meretyk, S; Native, O; Rubinov, R; Stein, A, 2007)
" The suramin dosing nomogram used in phase I and II portions of the trial yielded the desired plasma level of 10-50 micromol/L from 4."2.73Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma. ( Au, JJ; Bukowski, RM; Cooney, MM; Dreicer, R; Elson, P; Ganapathi, R; George, S; Mekhail, T; Rini, BI; Roman, S; Shen, T; Wientjes, GM, 2008)
"The median time to disease progression was 9."2.73[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy]. ( Ikeda, H; Kobayashi, M; Morita, T; Nakano, K; Nukui, A; Sugaya, Y; Suzuki, K; Yuzawa, M, 2008)
"This prospective trial aimed to evaluate the therapeutic effects and systemic toxicities of capecitabine monotherapy and capecitabine treatment combined with biological response modifiers in patients with metastatic renal cell carcinoma."2.71Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. ( Bartsch, R; Hussian, D; Kramer, G; Lintner, C; Locker, GJ; Mader, R; Marberger, M; Pluschnig, U; Rauchenwald, M; Steger, GG; Wenzel, C; Zielinski, CC, 2003)
"5-Fluorouracil was given at 750 mg m(-2) day(-1) on days 1-5 every 4 weeks."2.71Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. ( Bui, BN; Cany, L; Debled, M; Ferrière, JM; Gaston, R; Mathoulin-Pélissier, S; Palussière, J; Ravaud, A; Trufflandier, N, 2003)
"Metastatic renal cell carcinoma (RCC) has modest response rates to chemotherapy with gemcitabine and 5-fluorouracil (5-FU)."2.71A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. ( Rini, BI; Small, EJ; Weinberg, V, 2005)
"In total, 203 renal carcinoma patients' status post radical tumour nephrectomy were stratified into three risk groups: patients with tumour extending into renal vein/vena cava or invading beyond Gerota's fascia (pT3b/c pN0 or pT4pN0), patients with locoregional lymph node infiltration (pN+), and patients after complete resection of tumour relapse or solitary metastasis (R0)."2.71Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). ( Atzpodien, J; Ecke, M; Fornara, P; Gertenbach, U; Heynemann, H; Jentsch, H; Maskow, A; Reitz, M; Schmitt, E; Wandert, T; Wieland, W; Wöltjen, HH, 2005)
"The treatment of metastatic renal cell cancer remains unsatisfactory despite encouraging results with biotherapy."2.70Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10. ( Church, CK; DePriest, CB; Dillman, RO; Schulof, R; Soori, G; Stark, JJ; Tai, F; Wiemann, MC, 2002)
"The authors present the results of a six-year clinicoimmunological study of a therapeutic effect of cytkins combined with 5-fluoruracyl in metastatic renal-cell carcinoma."2.70[Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer]. ( Babich, VM; Bazalitskaia, SV; Gruzov, MA; Klimenko, IA; Kushneruk, IuI; Romanenko, AM; Shcherbak, AIu; Vozianov, AF; Zak, KP; Zubko, VI, 2002)
"Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells."2.70Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002)
"Chemotherapy resistance of renal cell carcinoma (RCC) has been attributed in large part to multidrug resistance (MDR)."2.70Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study. ( Chang, YH; Chen, KK; Chen, PM; Fan, FS; Liu, JH; Wang, WS; Yang, MH; Yen, CC, 2001)
"The median time to disease progression was 6."2.70A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma. ( Ryan, CW; Stadler, WM; Vogelzang, NJ, 2002)
" Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m(2)/week when combined with 5-fluorouracil (5-FU) at 200 mg/m(2)/day (Days 1-21) repeated every 4 weeks."2.70Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. ( Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ, 2001)
"Twenty-one patients with metastatic renal cell carcinoma (RCC) and a Cancer and Leukemia Group B performance status of 0 to 2 were enrolled."2.70A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma. ( Geoffroy, FJ; George, CM; Kollipara, P; Rini, BI; Stadler, WM; Vogelzang, NJ, 2002)
"Combination therapy of interferon-alpha plus 5-fluorouracil at the above-described dosage and schedule produced no better responses than interferon monotherapies."2.69Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer. ( Aiba, K; Igarashi, T; Kawamura, J; Kobayashi, M; Marumo, K; Onishi, T; Ozono, S; Satomi, Y; Terachi, T; Tomita, Y; Tsushima, T, 1999)
" During weeks 1 and 4, the dosage for rIL-2 was 10 MIU/m2 twice daily on days 3-5, and the dosage for IFN-alpha2B (Intron; Schering Plough, Kenilworth, NJ) was 6 MIU/m2 on day 1."2.69Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. ( Atkins, M; Clark, J; Dutcher, JP; Gordon, M; Logan, T; Lotze, M; Margolin, K; Mier, J; Plasse, T; Sosman, J; Weiss, G, 2000)
"55 patients with advanced renal cell cancer were treated as follows: IL-2 and IFN-alpha according to the schedule originally described by Atzpodien, with PVI 5FU 200 mg m(-2)day(-1)during weeks 5-9."2.69Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. ( Ahern, R; Allen, MJ; Bate, S; Eisen, T; Gore, ME; Johnston, S; Moore, J; Savage, P; Vaughan, M; Webb, A, 2000)
"In patients with metastatic renal cell carcinoma response rates of 7-26% have been achieved with immunotherapy."2.69Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party. ( De Mulder, PH; Groenewegen, G; Hoekman, K; Jansen, RL; Kruit, WH; Osanto, S; van Herpen, CM, 2000)
"Among 16 patients with renal cell carcinoma treated, four had major (clinical partial response) responses, one of which was demonstrated to be a pathologic clinical response after surgical resection of a residual mass."2.69Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma. ( Altobelli, KK; Binder, M; Clark, D; Elias, L; Mangalik, A; Morrison, B; Smith, A, 1999)
"Cimetidine is an H2-receptor antagonist used in the management of peptic ulcer disease and other hypersecretory gastrointestinal disorders."2.69A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma. ( Burch, PA; Creagan, ET; Dalton, RJ; Hatfield, AK; Maples, WJ; Pfeifle, DM; Poon, MA; Schaefer, PL; Suman, VJ; Veeder, MH, 1998)
"We report the results of the Subcutaneous Administration Propeukin Program (SCAPP) II trial of an outpatient treatment in renal cell carcinoma using interleukin-2 (IL-2) and interferon alfa-2a (IFN-alpha) administered subcutaneously in combination with fluorouracil (5-FU)."2.69Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Pr ( Abourachid, H; Andrieu, JM; Azagury, M; Benhammouda, A; Berdah, JF; Brewer, Y; Chastang, C; Chretien, Y; Di Palma, M; Guillet, P; Hauteville, D; Krakowski, I; Larregain-Fournier, D; Lucas, V; Malaurie, E; Mayeur, D; Mejean, A; Monnier, A; Paule, B; Pavlovitch, JM; Pfister, C; Salze, P; Tadrist, Z; Tourani, JM; Untereiner, M, 1998)
"Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b)."2.68[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma]. ( Fujinami, K; Ikeda, I; Kondo, I; Miura, T, 1996)
"Renal cell carcinoma is a common neoplasm that is often refractory to treatment."2.68A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study. ( Blumenstein, BA; Crawford, ED; Elias, L; Flanigan, RC; Goodwin, JW; Kish, J; Lowe, BA; Wade, JL, 1996)
"5-fluorouracil was administered at a dose of 600 mg/m2/day as a continuous infusions on Days 1-5."2.68Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. ( Amato, RJ; Banks, M; Ellerhorst, JA; Finn, LD; Logothetis, CJ; Millikan, RE; Sella, A; Tu, SM, 1997)
"Renal cell carcinoma is relatively resistant to both chemotherapy and immunotherapy."2.68Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon. ( Carpenter, C; Gebrosky, NP; Koukol, S; Lamm, DL; Nseyo, UO, 1997)
" None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU."2.68[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma]. ( Hosaka, M; Kubota, Y; Masuda, M; Noguchi, S; Shuin, T; Yao, M, 1995)
"In patients with progressive metastatic renal cell carcinoma, we established a three-drug combination comprising interferon-alpha (IFN-alpha), interleukin-2 (IL-2) and 5-fluorouracil (5-FU), using a regimen which allows outpatient therapy."2.67Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. ( Atzpodien, J; Deckert, M; Fenner, M; Hänninen, EL; Kirchner, H; Poliwoda, H, 1993)
"The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5."2.67Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. ( Bueschen, A; Crawford, ED; Flanigan, RC; Kish, JA; Leimert, JT; Neefe, JR; Wolf, M, 1994)
"Prednisone has been shown to decrease IFN-alpha-related toxicity without reducing the response rate."2.67Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study. ( Fosså, SD; Haarstad, H; Jacobsen, AB; Risberg, T; Schjølseth, SA, 1994)
"A total of 49 patients with metastatic renal cell cancer underwent recombinant interferon-alpha 2a therapy combined with chemotherapy."2.67Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. ( Amato, R; Dexeus, FH; Fitz, K; Kilbourn, R; Logothetis, CJ; Sella, A; Wallace, S, 1992)
"Responses in metastatic renal cell carcinoma appear confined to a favorable subset of patients."2.66Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma. ( Dexeus, FH; Finn, L; Logothetis, CJ; Sella, A, 1989)
" Future strategies should focus on investigating the immunomodulatory effects of chemotherapy in conjunction with TroVax, understanding the optimal dosing and schedule of the combination, and examining potential predictive biomarkers to determine which patients may benefit from immunotherapy from those who do not."2.50TroVax in colorectal cancer. ( Cen, P; Rowe, J, 2014)
"Metastatic renal cell carcinoma has a poor prognosis."2.43Immunotherapy in metastatic renal cell carcinoma. ( Bachmann, A; Haseke, N; Rohrmann, K; Siebels, M; Staehler, M; Stief, CG, 2005)
"Renal cell cancer is still a challenge not only concerning operative techniques (nephron-sparing techniques, established minimally-invasive techniques, such as laparoscopy, and experimental minimally-invasive techniques, such as cryoablation, radiofrequency ablation and others), but also with regard to the impact of systemic (immuno)therapy."2.42[Immunotherapy of renal cell carcinoma: results from current phase-III-trials]. ( Doehn, C; Jocham, D, 2004)
"Treatment of metastatic renal cell carcinoma (RCC) remains unsatisfactory."2.41Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. ( Bukowski, RM, 2000)
"In urinary bladder cancer, the combination chemotherapy with 5-FU and low-dose CDDP has been used as a radiosensitizer."2.40[Combination chemotherapy with 5-FU and low-dose CDDP for urogenital tumors]. ( Fujinami, K; Kubota, Y, 1999)
"The prognosis of metastatic renal cell cancer is unfavourable as neither chemo-, radiation- nor hormonal therapy achieve tumor remissions in more than 10% of the patients."2.38[Interferon-alpha therapy in hypernephroma]. ( Sagaster, KP, 1993)
"Clear cell renal cell carcinoma (ccRCC) has poor clinical outcomes and necessitates new treatment options."1.91Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA. ( Liu, D; Xu, M; Zhou, G, 2023)
"However, in clear cell renal cell carcinoma (ccRCC), p53 is rarely mutated, yet the tumors remain highly insensitive to the conventional chemotherapeutic drugs."1.46Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation. ( Cheng, Y; Ge, W; Han, Z; Hu, Y; Jiang, Q; Jiang, S; Li, H; Li, Z; Liu, T; Wang, X; Wu, Q; Wu, X; Yu, M; Yuan, J; Zhang, C; Zhao, K; Zhu, Y, 2017)
"BACKGROUND Renal cell carcinoma (RCC) is among the most common malignant cancers of males worldwide."1.46Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models. ( Cui, S, 2017)
"Using a cohort of 99 primary renal cell carcinoma samples, we showed that miR-21 expression in cancer tissues was higher than in adjacent non-tumor tissues whereas no significant difference was observed with stages, grades, and metastatic outcome."1.46Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma. ( Aubert, S; Cauffiez, C; Gaudelot, K; Gibier, JB; Glowacki, F; Gnemmi, V; Hémon, B; Leroy, X; Perrais, M; Pottier, N; Van Seuningen, I, 2017)
"Despite several therapeutic options renal cell carcinoma is associated with a poor clinical outcome."1.42Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase. ( Choi, EK; Hwang, JJ; Jeong, IG; Kang, JS; Kim, CS; Kim, MJ; Lee, JS; Lee, JY; Park, SE; Ro, S; Yi, HJ; Yun, J, 2015)
"However, its roles in clear cell renal cell carcinoma (RCC) are unclear."1.37The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma. ( Cao, K; Chen, J; Guo, S; Huang, B; Li, X; Mao, X; Mo, C; Pan, J; Qiu, S; Wang, Z; Zhuang, J, 2011)
" We then examined the antitumor effect of IAB-1 in combination with anticancer drugs against RCC."1.35Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma. ( Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J, 2008)
"An involvement of Pak1 in renal cell carcinoma (RCC), which remains highly refractory to chemotherapy and radiotherapy, remains to be investigated."1.34Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. ( Ambrose, M; Barry, OP; Casey, G; Houston, A; O'Sullivan, GC; Tangney, M, 2007)
"Treatment of renal cell carcinoma (RCC) is limited by its resistance to conventional chemotherapies."1.33Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas. ( Davidson, K; Gobe, GC; Johnson, DW; Li, J; Nicol, D; Pat, BK; Percy, C; Rennick, AJ, 2005)
"The results suggest that adenovirus-mediated IL-12 gene transfer combined with Ad."1.33Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice. ( Cho, WK; Hwang, KS; Im, DS; Kim, S; Yoo, J; Yun, HJ, 2005)
"The NC65 renal cell carcinoma line was used as a target."1.33Gene therapy with TRAIL against renal cell carcinoma. ( Hongo, F; Kawauchi, A; Kimura, Y; Matsubara, H; Miki, T; Mizutani, Y; Nakanishi, H; Sakata, T; Tamura, T; Ushijima, S, 2006)
"Renal cell carcinoma is an uncommon tumor in adults."1.33Solitary metastasis in a nasal fossa as the first manifestation of a renal carcinoma. ( Alcaide-García, J; Alés-Díaz, I; Benavides-Orgaz, M; Cobo-Dols, M; Gil-Calle, S; Gutiérrez-Calderón, V; Montesa-Pino, A; Villar-Chamorro, E, 2006)
"However, long-term survival of cytokine-treated, advanced renal cell carcinoma (RCC) patients remains a rare event and, thus, emphasizes the need for further investigations toward more effective therapies."1.33Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2. ( Atzpodien, J; Reitz, M, 2005)
"Metastatic renal cell cancer has a poor prognosis and survival."1.33Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience. ( Goldstein, D; Marx, G; Taylor, J, 2005)
"Conventional therapy for renal cell carcinoma (RCC) using interferon (IFN) has shown limited antitumor action."1.32Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma. ( Ishii, T; Marumo, K, 2004)
"5-Fluorouracil (5-FU) is an anticancer agent clinically used against various cancers including renal cell carcinoma (RCC)."1.32Significance of thymidylate synthase activity in renal cell carcinoma. ( Fukushima, M; Miki, T; Mizutani, Y; Nakao, M; Nonomura, M; Wada, H; Yoshida, O, 2003)
" These data indicate that rejection of primary and metastatic tumors can be achieved after intratumoral delivery of a nonviral IL-2 gene therapy, and is increased in combination with systemic delivery of a conventional chemotherapeutic agent."1.31Antitumoral effect of a nonviral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil. ( Batten, TL; Bishop, JS; Matar, M; Muller, S; Munger, WE; Pericle, F; Quezada, A; Thull, NM, 2000)
"Isoliquiritigenin is a chalcone isolated from licorice and shallots."1.31Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. ( Baba, M; Endo, H; Hamamoto, T; Joichi, Y; Kaneko, S; Morita, T; Nishino, H; Okada, Y; Okuyama, T; Tokue, A; Yamazaki, S, 2002)
"Conventional therapy for renal cell carcinoma using interferon (IFN) has shown limited antitumor action."1.30Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma. ( Marumo, K; Murai, M; Oya, M, 1997)
"The protocol for renal cell carcinoma consisted of combined chemotherapy with continuous infusion of 5-FU 250 mg/m2/day and CDDP 3 mg/m2/day in 2 weeks for 1 cycles (4 weeks)."1.30[Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma]. ( Hata, M; Ono, S; Ota, N; Otsuka, A, 1997)
"Immunotherapy management for advanced renal carcinoma has awaken a growing interest over the last few years."1.30[Immunotherapeutic treatment for metastatic renal carcinoma]. ( García Bueno, JM; Gutiérrez Sanz-Gadea, C; Hidalgo Pardo, F; Losada González, GP; Mus Malleu, A; Ozonas Moragues, M; Rebassa Llull, MJ, 1998)
"In patients with advanced metastatic renal cell carcinoma (RCC) seen at a single institution, the toxicity and long-term clinical effects of a combination therapy with recombinant interleukin-2 (rIL-2), recombinant interferon-alpha2 (rIFN-alpha2) and 5-fluorouracil (5-FU) were evaluated."1.30Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer. ( Allhoff, EP; Gruss, A; Reiher, F; Samland, D; Schmidt, U; Steinbach, F, 1999)
" In conclusion, we describe the predictive value of the number of lymphocytes from peripheral blood for the efficiency of IL-2/IFN-alpha-2b therapy in combination with 5-FU in patients with metastatic renal cell carcinoma."1.29Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU. ( Göhring, B; Heynemann, H; Langner, J; Rebmann, U; Riemann, D; Schabel, J, 1996)
"In metastatic renal cell carcinoma, most conventional antineoplastic drugs have yielded no or little efficacy."1.29Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma. ( Atzpodien, J; Lopez Hanninen, E; Poliwoda, H, 1995)
"Three patients with lung metastases of renal cell carcinoma (RCC) were treated with a combination of interferon-alpha, leucovorin and 5-fluorouracil."1.29[Three cases of lung metastases of renal cell carcinoma treated with a combination of interferon-alpha, 5-fluorouracil and leucovorin]. ( Demura, T; Hirakawa, K; Hirano, T; Ohashi, N; Sindoh, J; Tabata, T; Togashi, M, 1996)
"Renal cell carcinoma has been considered a tumor highly insensitive to conventional chemotherapy because of its multivariate biological potential, delayed manifestation of clinical symptoms and the lack of systematic investigation."1.29[Current status of chemotherapy for renal cell carcinoma]. ( Kato, T; Sato, K, 1994)
"Fourteen patients with metastatic renal cell carcinoma (RCC) were treated with high-dose folinic acid (HDFA): 200 mg/m2 i."1.28Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer. ( Ferrari, V; Marini, G; Marpicati, P; Montini, E; Simoncini, E; Zaniboni, A, 1989)
"A case of renal cell carcinoma with multiple lung metastases successfully treated with interferon (IFN) following nephrectomy is reported."1.28[A case of renal cell carcinoma with lung metastases successfully treated by interferon-beta]. ( Horie, M; Kawada, Y; Kobayashi, S; Komeda, H; Kuriyama, M; Takahashi, Y; Yamada, S, 1989)
"A metastatic renal cell carcinoma was found on the pelvic peritoneum and characteristic renal cancer cells were identified in the ascitic fluid."1.27[Synchronous double cancers in the ovary and kidney--a case report]. ( Fujiwara, A; Katsube, Y; Myoga, H; Nogawa, T; Ohta, S; Shigemasa, K; Shinko, Y; Tamaki, M, 1988)

Research

Studies (212)

TimeframeStudies, this research(%)All Research%
pre-19907 (3.30)18.7374
1990's59 (27.83)18.2507
2000's101 (47.64)29.6817
2010's43 (20.28)24.3611
2020's2 (0.94)2.80

Authors

AuthorsStudies
Liu, D1
Zhou, G1
Xu, M1
Cao, J1
Sun, X1
Zhang, X2
Chen, D1
Tsujino, T1
Takahara, K1
Matsunaga, T1
Yoshikawa, Y1
Takai, T1
Uchimoto, T1
Saito, K2
Tanda, N1
Hirano, H1
Nomi, H1
Ibuki, N1
Inamoto, T1
Azuma, H1
Wang, X4
Cheng, Y2
Zhu, Y1
Li, H2
Ge, W2
Wu, X1
Zhao, K2
Yuan, J1
Li, Z1
Jiang, S1
Han, Z1
Jiang, Q1
Wu, Q1
Liu, T1
Zhang, C2
Yu, M2
Hu, Y2
Cui, S1
Gaudelot, K1
Gibier, JB1
Pottier, N1
Hémon, B1
Van Seuningen, I1
Glowacki, F1
Leroy, X1
Cauffiez, C1
Gnemmi, V1
Aubert, S1
Perrais, M1
Hida, K1
Maishi, N1
Akiyama, K1
Ohmura-Kakutani, H1
Torii, C1
Ohga, N1
Osawa, T1
Kikuchi, H1
Morimoto, H1
Morimoto, M1
Shindoh, M1
Shinohara, N1
Hida, Y1
Cai, A1
Zhang, Y2
Han, F1
Zheng, W1
Zhou, CY1
Zhu, XQ1
Wang, XJ1
Li, ZY1
Chen, XC1
Chen, F1
Che, XY1
Xie, X1
Wei, R1
He, D1
Rustum, YM1
Chintala, S1
Durrani, FA1
Bhattacharya, A1
Lin, JA1
Fang, SU1
Su, CL1
Hsiao, CJ1
Chang, CC1
Lin, YF1
Cheng, CW1
Conter, HJ1
Lim, ZD2
Ng, CS2
Millikan, RE2
Tannir, NM5
Chen, B1
Duan, L1
Yin, G1
Tan, J1
Jiang, X1
Aitchison, M2
Bray, CA1
Van Poppel, H1
Sylvester, R2
Graham, J1
Innes, C1
McMahon, L1
Vasey, PA1
Bellmunt, J2
Suarez, C2
Gallardo, E1
Rodon, J1
Pons, F1
Bonfill, T1
Beltran, M1
Moya, I1
Galtes, S1
Albanell, J2
Carles, J3
Hagos, Y1
Wegner, W1
Kuehne, A1
Floerl, S1
Marada, VV1
Burckhardt, G1
Henjakovic, M1
Donini, M2
Buti, S3
Lazzarelli, S2
Bozzetti, R1
Rivoltini, L1
Camisaschi, C1
Castelli, C1
Bearz, A1
Simonelli, C2
Lo Re, G1
Mattioli, R2
Caminiti, C2
Passalacqua, R3
Kim, MJ1
Lee, JS2
Park, SE1
Yi, HJ1
Jeong, IG2
Kang, JS1
Yun, J1
Lee, JY1
Ro, S1
Choi, EK1
Hwang, JJ1
Kim, CS1
Rowe, J1
Cen, P1
Soerensen, AV1
Donskov, F1
Kjellberg, J1
Ibsen, R1
Hermann, GG1
Jensen, NV1
Fode, K1
Geertsen, PF1
Peng, J1
Mo, R1
Ma, J1
Fan, J1
Al-Hameed, FM1
Lacouture, ME1
Reilly, LM1
Gerami, P1
Guitart, J1
Thall, PF1
Wooten, L1
Siefker-Radtke, A1
Mathew, P1
Pagliaro, L1
Wood, C1
Jonasch, E4
Marur, S1
Eliason, J1
Heilbrun, LK1
Dickow, B1
Smith, DW1
Baranowski, K1
Alhasan, S1
Vaishampayan, U1
Yamamoto, K3
Mizutani, Y8
Nakanishi, H5
Fujiwara, J1
Ishida, H1
Toiyama, D1
Abe, K1
Hayashi, I1
Okada, K1
Kawauchi, A2
Mizuno, M1
Yoshida, J1
Miki, T6
Moriya, F1
Ogasawara, S1
Basaki, Y3
Akiba, J1
Kojiro, S1
Fukahori, S1
Ishizaki, H1
Nishida, N1
Matsuoka, K1
Kojiro, M1
Kuwano, M1
Yano, H1
George, S1
Dreicer, R1
Au, JJ1
Shen, T1
Rini, BI5
Roman, S1
Cooney, MM1
Mekhail, T1
Elson, P2
Wientjes, GM1
Ganapathi, R1
Bukowski, RM3
Harshman, LC1
Li, M1
Srinivas, S1
Daliani, DD1
Papandreou, CN1
Swisher, S1
Wood, CG1
Swanson, DA2
Logothetis, CJ5
Soga, N1
Yamada, Y4
Nishikawa, K1
Hasegawa, Y1
Kise, H1
Arima, K1
Sugimura, Y1
Van Veldhuizen, PJ1
Hussey, M1
Lara, PN1
Mack, PC1
Gandour-Edwards, R1
Clark, JI1
Lange, MK1
Crawford, DE1
Yuen, JS1
Akkaya, E1
Wang, Y1
Takiguchi, M1
Peak, S1
Sullivan, M1
Protheroe, AS1
Macaulay, VM1
Kraemer, A1
Hauser, S2
Kim, Y1
Gorschlüter, M1
Müller, SC3
Brossart, P1
Schmidt-Wolf, IG1
Sunela, KL1
Koskinen, S1
Kellokumpu-Lehtinen, PL1
Liu, JZ1
Chen, SG1
Zhang, B1
Wang, CB1
Zhao, XW1
Li, GY1
Wang, LX1
Serrano, C1
Andreu, J1
Tai, CJ1
Gore, ME3
Griffin, CL1
Hancock, B1
Patel, PM1
Pyle, L2
James, N1
Oliver, RT2
Mardiak, J1
Hussain, T1
Parmar, MK1
Royston, P1
Mulders, PF2
Trigo, JM1
Calvo, E1
Pérez-Gracia, JL1
Rubió, J1
Virizuela, JA1
López, R1
Lázaro, M1
Escudier, B5
Ravaud, A4
Grossgoupil, M1
Goodsaid, FM1
Amur, S1
Aubrecht, J1
Burczynski, ME1
Carl, K1
Catalano, J1
Charlab, R1
Close, S1
Cornu-Artis, C1
Essioux, L1
Fornace, AJ1
Hinman, L1
Hong, H1
Hunt, I1
Jacobson-Kram, D1
Jawaid, A1
Laurie, D1
Lesko, L1
Li, HH1
Lindpaintner, K1
Mayne, J1
Morrow, P1
Papaluca-Amati, M1
Robison, TW1
Roth, J1
Schuppe-Koistinen, I1
Shi, L1
Spleiss, O1
Tong, W1
Truter, SL1
Vonderscher, J1
Westelinck, A1
Zhang, L1
Zineh, I1
Chiesa, MD2
Re, GL1
Lheshi, A1
Simon, S1
Mazza, G1
Zhong, Y1
Guan, K1
Guo, S2
Zhou, C1
Wang, D1
Ma, W1
Li, C1
Zhang, S1
Tagawa, ST1
Milowsky, MI1
Jeske, S1
Mazumdar, M1
Kung, S1
Sung, M1
Lehrer, D1
Matulich, D1
Selzer, J1
Wright, JJ1
Nanus, DM1
Richey, SL1
Ng, C1
Bierer, S2
Hoffmeister, I1
Gerss, J1
Herrmann, E2
Wülfing, C2
Sibrowski, W1
Hertle, L3
Kelsch, R1
Lal, LS1
Atkinson, BJ1
Byfield, SD1
Miller, LA1
Pagliaro, LC1
Feng, C1
Porta, C1
Paglino, C1
Tsimafeyeu, I1
Demidov, L1
Kharkevich, G1
Petenko, N1
Galchenko, V1
Sinelnikov, I1
Naidzionak, U1
Takeuchi, A1
Shiota, M1
Tatsugami, K1
Yokomizo, A1
Eto, M1
Inokuchi, J1
Kuroiwa, K1
Kiyoshima, K1
Naito, S1
Chang, HR1
Chen, PN1
Yang, SF1
Sun, YS1
Wu, SW1
Hung, TW1
Lian, JD1
Chu, SC1
Hsieh, YS1
Walter, B1
Schrettenbrunner, I1
Vogelhuber, M1
Grassinger, J1
Bross, K1
Wilke, J1
Suedhoff, T1
Berand, A1
Wieland, WF1
Rogenhofer, S1
Andreesen, R1
Reichle, A1
Gilles, R1
de Geus-Oei, LF1
Oyen, WJ1
Huang, B1
Cao, K1
Li, X1
Mao, X1
Wang, Z1
Zhuang, J1
Pan, J1
Mo, C1
Chen, J1
Qiu, S1
Hughes, C1
Brown, MD1
Clarke, NW1
Flower, KR1
Gardner, P1
Bronchud, MH1
Castillo, S1
Escriva de Romaní, S1
Mourelo, S1
Fernández, A1
Baena, C1
Murillo, J1
Julia, JC1
Esquius, J1
Romero, R1
Andreu, X1
Ryan, CW2
Vogelzang, NJ7
Stadler, WM9
Atzpodien, J14
Hoffmann, R2
Franzke, M1
Stief, C1
Wandert, T5
Reitz, M7
Desai, AA2
Ansari, R1
Krauss, S1
Gez, E3
Rubinov, R3
Gaitini, D2
Meretyk, S2
Best, LA2
Native, O2
Stein, A3
Erlich, N1
Beny, A1
Zidan, J1
Haim, N2
Kuten, A3
Bennouna, J1
Delva, R1
Gomez, F3
Lesimple, T3
Geoffrois, L2
Linassier, C2
Chevreau, C2
Douillard, JY3
Négrier, S3
Hirano, Y3
Takayama, T3
Kageyama, S2
Ushiyama, T3
Suzuki, K4
Fujita, K4
Vozianov, AF1
Zak, KP1
Zubko, VI1
Romanenko, AM1
Klimenko, IA1
Babich, VM1
Kushneruk, IuI1
Shcherbak, AIu1
Bazalitskaia, SV1
Gruzov, MA1
Wada, H3
Yoshida, O5
Fukushima, M4
Nonomura, M1
Nakao, M2
Roigas, J3
Deger, S1
Taymoorian, K1
Wille, AH1
Johannsen, M1
Türk, I1
Schnorr, D1
Loening, SA2
Amato, RJ6
Huo, D1
George, C1
Yang, X1
Karrison, T1
Zimmerman, TM1
Wenzel, C2
Locker, GJ2
Bartsch, R1
Pluschnig, U1
Mader, R2
Hussian, D1
Kramer, G2
Marberger, M2
Lintner, C1
Rauchenwald, M2
Zielinski, CC2
Steger, GG2
Trufflandier, N1
Ferrière, JM1
Debled, M1
Palussière, J1
Cany, L1
Gaston, R1
Mathoulin-Pélissier, S1
Bui, BN1
Kirchner, H8
Jonas, U2
Bergmann, L1
Schott, H2
Heynemann, H4
Fornara, P3
Bodenstein, H1
Pomer, S1
Metzner, B3
Rebmann, U4
Oberneder, R1
Siebels, M3
Puchberger, T1
Rathmell, WK1
Malkowicz, SB1
Holroyde, C1
Luginbuhl, W1
Vaughn, DJ1
O'Brien, MF1
Rea, D1
Rogers, E1
Bredin, H1
Butler, M1
Grainger, R1
McDermott, TE1
Mullins, G1
O'Brien, A1
Twomey, A1
Thornhill, J1
Wu, XX3
Ogawa, O5
Kakehi, Y4
Doehn, C2
Jocham, D2
May, M1
Helke, C1
Bock, M1
Hoschke, B1
Rexer, H1
Waters, JS1
Moss, C1
James, M1
Hackett, S1
A'hern, R1
Gore, M1
Eisen, T2
Ishii, T1
Marumo, K3
Anderson, DA1
Woltman, ML1
Kovach, G1
Konety, BR1
Ikemoto, S1
Sugimura, K1
Yoshida, N1
Kuratsukuri, K1
Wada, S1
Nakatani, T2
Weinberg, V1
Small, EJ2
Marx, G1
Taylor, J1
Goldstein, D1
Wang, HJ1
Chen, HX1
Li, HZ1
Davidson, K1
Percy, C1
Rennick, AJ1
Pat, BK1
Li, J1
Nicol, D1
Johnson, DW1
Gobe, GC1
Schmitt, E1
Gertenbach, U2
Maskow, A1
Ecke, M1
Wöltjen, HH1
Jentsch, H1
Wieland, W1
Rohrmann, K1
Staehler, M1
Haseke, N1
Bachmann, A1
Stief, CG1
Brinkmann, OA2
Bruns, F1
Gosheger, G1
Micke, O1
Hwang, KS1
Cho, WK1
Yoo, J1
Yun, HJ1
Kim, S1
Im, DS1
Dilhuydy, MS1
Rawat, A1
Hong, SK2
Kwak, C2
Lee, SE2
Byun, SS1
Gill, MC1
Chang, IH1
Kim, YJ1
Cobo-Dols, M1
Alés-Díaz, I1
Villar-Chamorro, E1
Gil-Calle, S1
Alcaide-García, J1
Montesa-Pino, A1
Gutiérrez-Calderón, V1
Benavides-Orgaz, M1
Soder, M1
Raschke, R1
Salm, S1
Schwindl, B1
Leiber, C1
Huland, E1
Heinzer, H1
Siemer, S1
Halabi, S1
Rini, B1
Ernstoff, MS1
Davila, E1
Picus, J1
Barrier, R1
Matsubara, H1
Hongo, F1
Kimura, Y1
Ushijima, S1
Tamura, T1
Sakata, T1
Bode, ME1
Köpke, T1
Bögemann, M1
Varan, A1
Akyuz, C1
Sari, N1
Buyukpamukçu, N1
Cağlar, M1
Buyukpamukçu, M1
Shang, D2
Ito, N2
Watanabe, J1
Awakura, Y1
Nishiyama, H1
Kamoto, T2
Mashiach, T1
Quinn, DI1
Bukowski, R1
Poiesz, B1
Kardinal, CG1
Lewis, N1
Makalinao, A1
Murray, P1
Torti, FM1
Petrioli, R1
Paolelli, L1
Francini, E1
Marsili, S1
Pascucci, A1
Sciandivasci, A1
de Rubertis, G1
Barbanti, G1
Manganelli, A1
Salvestrini, F1
Francini, G1
O'Sullivan, GC1
Tangney, M1
Casey, G1
Ambrose, M1
Houston, A1
Barry, OP1
Khan, M1
Merseburger, AS1
Kuczyk, MA1
Brighenti, M1
Bongiovanni, C1
Buzio, C1
Alberici, F1
Han, KS1
Joung, JY1
Choi, WS1
Hwang, SS1
Yang, SO1
Seo, HK1
Chung, J1
Lee, KH1
Kobayashi, M2
Nakano, K1
Ikeda, H1
Nukui, A1
Sugaya, Y1
Yuzawa, M1
Morita, T4
Ju, SA1
Cheon, SH1
Park, SM1
Tam, NQ1
Kim, YM1
An, WG1
Kim, BS1
Mohammad, T1
Satomi, Y2
Senga, Y1
Fukuda, M1
Nakahashi, M1
Ohshima, H1
Furuhata, A1
Lopez Hänninen, E3
Duensing, S1
Franzke, A4
Buer, J3
Probst, M1
Anton, P1
Poliwoda, H4
Ueno, NT1
Zukiwski, AA2
Imai, T2
Katagiri, A2
Tomita, Y3
Noguchi, S1
Shuin, T1
Kubota, Y2
Masuda, M1
Yao, M1
Hosaka, M1
Sella, A6
Kilbourn, RG1
Gray, I1
Finn, L2
Ellerhorst, J2
Kimura, M1
Saitoh, K1
Sato, S1
Kish, JA1
Wolf, M1
Crawford, ED2
Leimert, JT1
Bueschen, A1
Neefe, JR1
Flanigan, RC3
Haarstad, H1
Jacobsen, AB1
Schjølseth, SA1
Risberg, T1
Fosså, SD1
Hänninen, EL2
Deckert, M2
Fenner, M2
Sagaster, KP1
Körfer, A1
Menzel, T1
Kato, T1
Sato, K1
Puduvalli, VK1
Austin, SG1
Forman, AD1
Hofmockel, G2
Langer, W2
Theiss, M2
Gruss, A3
Frohmüller, HG1
Togashi, M1
Tabata, T1
Hirakawa, K1
Ohashi, N1
Sindoh, J1
Hirano, T1
Demura, T1
Elias, L3
Blumenstein, BA1
Kish, J1
Wade, JL2
Lowe, BA1
Goodwin, JW1
Gutman, M1
Abu-Abid, S1
Sorkine, P1
Inbar, M1
Lev, D1
Chen, Z1
Oron, D1
Chaitchik, S1
Klausner, JM1
Fujinami, K2
Ikeda, I1
Miura, T1
Kondo, I1
Göhring, B1
Riemann, D1
Schabel, J1
Langner, J1
Frohmüller, H1
Oya, M1
Murai, M1
Banks, RE1
Forbes, MA1
Hallam, S1
Jenkins, A1
Wadhwa, M1
Dilger, P1
Meager, A1
Thorpe, R1
Bowmer, CJ1
Joffe, JK1
Patel, P1
Johnson, PW1
Selby, PJ1
Thiounn, N1
Pages, F1
Flam, T1
Tartour, E1
Mosseri, V1
Zerbib, M1
Beuzeboc, P1
Deneux, L1
Fridman, WH1
Debré, B1
Loyer, E1
David, C1
Breul, J1
Tief, G1
Hartung, R1
Ellerhorst, JA1
Tu, SM1
Finn, LD1
Banks, M1
Gebrosky, NP1
Koukol, S1
Nseyo, UO1
Carpenter, C1
Lamm, DL1
Otsuka, A1
Ono, S1
Hata, M1
Ota, N1
Figlin, R1
Gitlitz, B1
Franklin, J1
Dorey, F1
Moldawer, N1
Rausch, J1
deKernion, J1
Belldegrun, A1
Hidalgo Pardo, F1
Gutiérrez Sanz-Gadea, C1
Rebassa Llull, MJ1
García Bueno, JM1
Mus Malleu, A1
Losada González, GP1
Ozonas Moragues, M1
Kanematsu, A1
Inoue, T1
Nakano, T1
Segawa, T1
Hiura, M1
Hashimura, T1
Tourani, JM1
Pfister, C1
Berdah, JF1
Benhammouda, A1
Salze, P1
Monnier, A1
Paule, B1
Guillet, P1
Chretien, Y1
Brewer, Y1
Di Palma, M1
Untereiner, M1
Malaurie, E1
Tadrist, Z1
Pavlovitch, JM1
Hauteville, D1
Mejean, A1
Azagury, M1
Mayeur, D1
Lucas, V1
Krakowski, I1
Larregain-Fournier, D1
Abourachid, H1
Andrieu, JM1
Chastang, C1
Audhuy, B1
Caty, A2
Ferrero, JM1
Drevon, M1
Creagan, ET1
Veeder, MH1
Suman, VJ1
Burch, PA1
Maples, WJ1
Schaefer, PL1
Pfeifle, DM1
Dalton, RJ1
Hatfield, AK1
Poon, MA1
Igarashi, T1
Onishi, T1
Aiba, K1
Tsushima, T1
Ozono, S1
Terachi, T2
Kawamura, J1
Van Kuilenburg, AB1
van Lenthe, H1
Blom, MJ1
Mul, EP1
Van Gennip, AH1
Samland, D1
Steinbach, F1
Reiher, F1
Schmidt, U1
Allhoff, EP1
Binder, M1
Mangalik, A1
Clark, D1
Morrison, B1
Altobelli, KK1
Smith, A1
Mekori, T1
Struminger, L1
Nativ, O1
Tippin, DB1
Reeves, W1
Tokue, A3
Yonekura, K2
Chikahisa, L2
Okabe, S2
Hashimoto, A2
Miyadera, K2
Wierzba, K2
Nishiyama, M1
Yamamoto, W1
Park, JS1
Okamoto, R1
Hanaoka, H1
Takano, H1
Saito, N1
Matsukawa, M1
Shirasaka, T1
Kurihara, M1
van Herpen, CM1
Jansen, RL1
Kruit, WH1
Hoekman, K1
Groenewegen, G1
Osanto, S1
De Mulder, PH1
Dumas, MC1
Taber, DA1
Lew, D1
Figlin, RA1
Thompson, ME1
Triozzi, PL1
Belt, RJ1
Wood, DP1
Rivkin, SE1
David, E1
Oevermann, K1
Schrader, A1
Patzelt, T2
Bishop, JS1
Thull, NM1
Matar, M1
Quezada, A1
Munger, WE1
Batten, TL1
Muller, S1
Pericle, F1
Allen, MJ1
Vaughan, M1
Webb, A1
Johnston, S1
Savage, P1
Bate, S1
Moore, J1
Ahern, R1
Dutcher, JP1
Logan, T1
Gordon, M1
Sosman, J1
Weiss, G1
Margolin, K1
Plasse, T1
Mier, J1
Lotze, M1
Clark, J1
Atkins, M1
Rossi, JF1
Viens, P1
Amato, R2
Matsuzaki, A1
Liu, JH1
Yang, MH1
Fan, FS1
Yen, CC1
Wang, WS1
Chang, YH1
Chen, KK1
Chen, PM1
Olencki, T1
Peereboom, D1
Wood, L1
Budd, GT1
Novick, A1
Finke, J1
McLain, D1
Lu, J1
Illiger, HJ1
Ukena, D1
Funke, PJ1
Gramatzki, M1
Jürgenson, S1
Mani, S1
Bertucci, D1
Schilsky, RL1
Ratain, MJ1
Bonavida, B1
Schmidinger, M1
Probst-Kepper, M1
Lindig, C1
Framzle, M1
Schrader, AJ1
Ganser, A1
Yanai, Y1
Horie, S1
Yamauchi, H1
Ikegami, H1
Kurimoto, M1
Kitamura, T1
George, CM1
Geoffroy, FJ1
Kollipara, P1
Aoyagi, K1
Soori, G1
Dillman, RO1
Wiemann, MC1
Stark, JJ1
Tai, F1
DePriest, CB1
Church, CK1
Schulof, R1
Yamazaki, S1
Endo, H1
Hamamoto, T1
Baba, M1
Joichi, Y1
Kaneko, S1
Okada, Y1
Okuyama, T1
Nishino, H1
Murphy, BR1
Rynard, SM1
Einhorn, LH1
Loehrer, PJ1
Nishimura, N1
Kanda, S1
Yogi, Y1
Kawamura, M1
Nakamura, M1
Hyakutake, H1
Kanetake, H1
Saito, Y1
Fitz, K1
Dexeus, FH2
Kilbourn, R1
Wallace, S1
Sasagawa, T1
Munakata, A1
Muramatsu, T1
Honda, N1
Fukatsu, H1
Segawa, A1
Hirata, N1
Senda, H1
Hrushesky, WJ1
Fujioka, T1
Hasegawa, M1
Ishikura, K1
Nomura, K1
Okamoto, T1
Tanji, S1
Koike, H1
Kubo, T1
Zaniboni, A1
Simoncini, E1
Marpicati, P1
Montini, E1
Ferrari, V1
Marini, G1
Komeda, H1
Horie, M1
Takahashi, Y1
Kobayashi, S1
Yamada, S1
Kuriyama, M1
Kawada, Y1
Asakawa, M1
Maekawa, T1
Umeda, M1
Sakamoto, W1
Senju, M1
Iseki, T1
Tanaka, H1
Horii, A1
Myoga, H1
Tamaki, M1
Shinko, Y1
Ohta, S1
Shigemasa, K1
Nogawa, T1
Katsube, Y1
Fujiwara, A1
Masuda, F1
Suzuki, M1
Ohnishi, T1
Nakada, J1
Mori, Y1
Iizuka, N1
Machida, T1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb in Metastatic reNal Cell Carcinoma[NCT04462445]Phase 225 participants (Actual)Interventional2015-06-25Completed
A Phase II Study of IV Gemcitabine and Oral Capecitabine in Patients With Advanced Renal Cell Cancer[NCT00058318]Phase 243 participants (Actual)Interventional2004-12-31Completed
A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma[NCT00053820]Phase 3670 participants (Anticipated)Interventional2002-07-31Completed
Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)[NCT00496301]Phase 240 participants (Anticipated)Interventional2006-11-30Completed
Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients[NCT01182142]Phase 251 participants (Anticipated)Interventional2007-09-30Completed
A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma[NCT00042965]Phase 260 participants (Actual)Interventional2002-10-31Completed
A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma[NCT00003126]Phase 369 participants (Actual)Interventional1997-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

12 reviews available for fluorouracil and Adenocarcinoma Of Kidney

ArticleYear
TroVax in colorectal cancer.
    Human vaccines & immunotherapeutics, 2014, Volume: 10, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines

2014
Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:6

    Topics: Alanine Transaminase; Azetidines; Benzylamines; Carcinoma, Renal Cell; Drug Approval; Europe; Fluoro

2010
Thalidomide therapy for renal cell carcinoma.
    Critical reviews in oncology/hematology, 2003, Jun-27, Volume: 46 Suppl

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cape

2003
[Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
    Aktuelle Urologie, 2004, Volume: 35, Issue:2

    Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemothe

2004
Immunotherapy in metastatic renal cell carcinoma.
    World journal of urology, 2005, Volume: 23, Issue:3

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2005
Interferon alpha for the treatment of advanced renal cancer.
    Expert opinion on biological therapy, 2005, Volume: 5, Issue:6

    Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Combined Modality T

2005
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
    Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:6 Suppl 5

    Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II

2006
Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma?
    Seminars in urology, 1993, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Clinical Trials as

1993
[Interferon-alpha therapy in hypernephroma].
    Wiener medizinische Wochenschrift (1946), 1993, Volume: 143, Issue:16-17

    Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Interferon-alpha; In

1993
European studies of interleukin-2 in metastatic renal cell carcinoma.
    Seminars in oncology, 1993, Volume: 20, Issue:6 Suppl 9

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell;

1993
[Combination chemotherapy with 5-FU and low-dose CDDP for urogenital tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Combined Modality

1999
Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma.
    Seminars in oncology, 2000, Volume: 27, Issue:2

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce

2000

Trials

83 trials available for fluorouracil and Adenocarcinoma Of Kidney

ArticleYear
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disea

2014
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
    The oncologist, 2014, Volume: 19, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; De

2014
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
    Targeted oncology, 2015, Volume: 10, Issue:2

    Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolite

2015
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
    The Journal of urology, 2008, Volume: 180, Issue:3

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal

2008
Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
    Urology, 2008, Volume: 72, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2008
Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.
    Clinical genitourinary cancer, 2008, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat

2008
The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    American journal of clinical oncology, 2008, Volume: 31, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Renal

2008
Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2009, Volume: 16, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dr

2009
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
    American journal of clinical oncology, 2009, Volume: 32, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C

2009
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide.
    German medical science : GMS e-journal, 2009, Jun-10, Volume: 7

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycyt

2009
A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Re

2010
Effect of haishengsu as an adjunct therapy for patients with advanced renal cell cancer: a randomized and placebo-controlled clinical trial.
    Journal of alternative and complementary medicine (New York, N.Y.), 2009, Volume: 15, Issue:10

    Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arcidae; C

2009
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
    Lancet (London, England), 2010, Feb-20, Volume: 375, Issue:9715

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2010
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C

2010
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2010, Volume: 33, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem

2010
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
    American journal of clinical oncology, 2011, Volume: 34, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabin

2011
Phase II, multicenter, uncontrolled trial of single-agent capecitabine in patients with non-clear cell metastatic renal cell carcinoma.
    American journal of clinical oncology, 2012, Volume: 35, Issue:3

    Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Papillary; Ca

2012
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Age

2012
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
    Cancer, 2002, May-15, Volume: 94, Issue:10

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

2002
Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma.
    Cancer, 2002, Sep-01, Volume: 95, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2002
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
    Cancer, 2002, Oct-15, Volume: 95, Issue:8

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal

2002
Interleukin-2, interferon-alpha, 5-fluorouracil, and vinblastine in the treatment of metastatic renal cell carcinoma: a prospective phase II study: the experience of Rambam and Lin Medical Centers 1996-2000.
    Cancer, 2002, Oct-15, Volume: 95, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel

2002
A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma.
    Oncology, 2003, Volume: 64, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour

2003
[Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer].
    Likars'ka sprava, 2002, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug S

2002
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
    The Journal of urology, 2003, Volume: 170, Issue:4 Pt 1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce

2003
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
    Anti-cancer drugs, 2003, Volume: 14, Issue:10

    Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Ther

2003
Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.
    British journal of cancer, 2003, Dec-15, Volume: 89, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progress

2003
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Apr-01, Volume: 22, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur

2004
Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer.
    American journal of clinical oncology, 2004, Volume: 27, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; Interfe

2004
Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
    European urology, 2004, Volume: 45, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour

2004
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
    British journal of cancer, 2004, Nov-15, Volume: 91, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyt

2004
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
    Cancer, 2005, Feb-01, Volume: 103, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci

2005
Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    British journal of cancer, 2005, Mar-14, Volume: 92, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Fluorourac

2005
Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation.
    World journal of urology, 2005, Volume: 23, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P

2005
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
    Investigational new drugs, 2006, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ca

2006
Interleukin-2/interferon-alpha2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).
    British journal of cancer, 2006, Aug-21, Volume: 95, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; De

2006
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
    Cancer, 2006, Sep-15, Volume: 107, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyti

2006
Immuno-chemotherapy in metastatic renal cell carcinoma: long-term results from the rambam and linn medical centers, Haifa, Israel.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel

2007
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

2008
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
    Anti-cancer drugs, 2007, Volume: 18, Issue:7

    Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; De

2007
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:6

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

2008
[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycyti

2008
Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell cancer.
    Journal of experimental therapeutics & oncology, 2008, Volume: 7, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car

2008
Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
    World journal of urology, 1995, Volume: 13, Issue:3

    Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Rena

1995
[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 1995, Volume: 41, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Sch

1995
Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
    Cancer biotherapy, 1994,Summer, Volume: 9, Issue:2

    Topics: Adult; Aged; Blood Cell Count; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Fluorouraci

1994
Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study.
    Cancer, 1994, Aug-01, Volume: 74, Issue:3

    Topics: Carcinoma, Renal Cell; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Parent

1994
Interferon-alpha, 5-FU and prednisone in metastatic renal cell carcinoma: a phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug

1994
Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A Suppl 5

    Topics: Adult; Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Administration Schedule; Female;

1993
European studies of interleukin-2 in metastatic renal cell carcinoma.
    Seminars in oncology, 1993, Volume: 20, Issue:6 Suppl 9

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell;

1993
Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.
    The Journal of urology, 1996, Volume: 156, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Combined

1996
A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
    Cancer, 1996, Sep-01, Volume: 78, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protoc

1996
Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer.
    Cancer, 1996, Sep-01, Volume: 78, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma

1996
[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:12

    Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce

1996
Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.
    Cancer, 1997, Dec-01, Volume: 80, Issue:11

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin

1997
Treatment of renal cell carcinoma with 5-fluorouracil and alfa-interferon.
    Urology, 1997, Volume: 50, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorourac

1997
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    The cancer journal from Scientific American, 1997, Volume: 3 Suppl 1

    Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; K

1997
[Combination therapy of daily intramuscular injection of interferon-alpha and oral administration of fluorouracil for advanced renal cell carcinoma].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1998, Volume: 89, Issue:3

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell;

1998
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Pr
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:7

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell;

1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour

1998
A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma.
    American journal of clinical oncology, 1998, Volume: 21, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cimetidine; Fema

1998
Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer.
    Urology, 1999, Volume: 53, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur

1999
Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma.
    American journal of clinical oncology, 1999, Volume: 22, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administrat

1999
T-cell subpopulation in patients with metastatic renal cell carcinoma treated by recombinant interleukin-2, recombinant interferon-alpha, 5-fluorouracil, and vinblastine.
    Cancer investigation, 1999, Volume: 17, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit

1999
Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    British journal of cancer, 2000, Volume: 82, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Hu

2000
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel

2000
Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study.
    Cancer, 2000, Aug-01, Volume: 89, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour

2000
Capecitabine in the treatment of metastatic renal cell carcinoma.
    British journal of cancer, 2000, Volume: 83, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Renal Cell; Deoxy

2000
Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    British journal of cancer, 2000, Volume: 83, Issue:8

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-

2000
Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit

2000
Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur

2000
Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.
    Urology, 2001, Volume: 57, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel

2001
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
    Journal of cancer research and clinical oncology, 2001, Volume: 127, Issue:5

    Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chills; Combined Moda

2001
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial.
    British journal of cancer, 2001, Oct-19, Volume: 85, Issue:8

    Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; K

2001
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Cancer, 2001, Sep-15, Volume: 92, Issue:6

    Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco

2001
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 39, Issue:1

    Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D

2002
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxy

2002
Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Cancer biotherapy & radiopharmaceuticals, 2002, Volume: 17, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cel

2002
A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study.
    Investigational new drugs, 1992, Volume: 10, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorourac

1992
Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
    The Journal of urology, 1992, Volume: 147, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Dr

1992
Cancer chronotherapy: a drug delivery challenge.
    Progress in clinical and biological research, 1990, Volume: 341A

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Circadian Rhythm; Colorectal Neoplasms; Drug

1990
Interferon alternating with chemotherapy for patients with metastatic renal cell carcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Clinical Trials as

1989
[Comparative clinical study of single and combination therapy of human lymphoblastoid interferon (HLBI) with 5-FU in the treatment of advanced renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 1989, Volume: 35, Issue:8

    Topics: Administration, Oral; Aged; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Fluorouracil;

1989

Other Studies

118 other studies available for fluorouracil and Adenocarcinoma Of Kidney

ArticleYear
Preclinical Evidence that Arctigenin Effectively and Selectively Targets Clear Cell Renal Cell Carcinoma Via Suppressing EGFR and RhoA.
    Nutrition and cancer, 2023, Volume: 75, Issue:5

    Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorouracil;

2023
6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.
    The American journal of the medical sciences, 2020, Volume: 360, Issue:3

    Topics: AMP-Activated Protein Kinases; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cellular Reprogra

2020
Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report.
    Journal of medical case reports, 2017, Apr-10, Volume: 11, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Colostomy; Fluo

2017
Epigenetic silencing of ASPP1 confers 5-FU resistance in clear cell renal cell carcinoma by preventing p53 activation.
    International journal of cancer, 2017, 10-01, Volume: 141, Issue:7

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis

2017
Immunogenic Chemotherapy Sensitizes Renal Cancer to Immune Checkpoint Blockade Therapy in Preclinical Models.
    Medical science monitor : international medical journal of experimental and clinical research, 2017, Jul-11, Volume: 23

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Renal Cell; Cell

2017
Targeting miR-21 decreases expression of multi-drug resistant genes and promotes chemosensitivity of renal carcinoma.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2017, Volume: 39, Issue:7

    Topics: Antagomirs; Apoptosis; Benzimidazoles; Carcinoma, Renal Cell; Cation Transport Proteins; Cell Line,

2017
Tumor endothelial cells with high aldehyde dehydrogenase activity show drug resistance.
    Cancer science, 2017, Volume: 108, Issue:11

    Topics: Aldehyde Dehydrogenase; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Lineage; Drug Resista

2017
HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma.
    Cancer letters, 2018, 09-28, Volume: 432

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Papil

2018
Oridonin enhances the cytotoxicity of 5-FU in renal carcinoma cells by inducting necroptotic death.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 106

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; Cell Line

2018
Role of SIRT2 in Regulation of Stemness of Cancer Stem-Like Cells in Renal Cell Carcinoma.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 49, Issue:6

    Topics: AC133 Antigen; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Fluorouracil; H

2018
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma-Bench-to-Bedside Therapy.
    International journal of molecular sciences, 2018, Oct-29, Volume: 19, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Hel

2018
Silencing glucose-regulated protein 78 induced renal cell carcinoma cell line G1 cell-cycle arrest and resistance to conventional chemotherapy.
    Urologic oncology, 2014, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Carcinogenesis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation;

2014
Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
    Clinical genitourinary cancer, 2013, Volume: 11, Issue:3

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Hu

2013
miR-381, a novel intrinsic WEE1 inhibitor, sensitizes renal cancer cells to 5-FU by up-regulation of Cdc2 activities in 786-O.
    Journal of chemotherapy (Florence, Italy), 2013, Volume: 25, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Renal Cell; CDC2 Protein Kinas

2013
HNF4α induced chemosensitivity to oxaliplatin and 5-FU mediated by OCT1 and CNT3 in renal cell carcinoma.
    Journal of pharmaceutical sciences, 2014, Volume: 103, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Fluorouracil; Hepatocyte Nuclear Fac

2014
Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.
    The Journal of urology, 2015, Volume: 193, Issue:5

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2015
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
    European urology, 2015, Volume: 68, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bev

2015
let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma.
    World journal of surgical oncology, 2015, May-08, Volume: 13

    Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis;

2015
Saddle pulmonary embolus and bronchiolitis obliterans with organizing pneumonia develop simultaneously after first cyclophosphamide, methotrexate, 5FU chemotherapy for breast cancer.
    Saudi medical journal, 2015, Volume: 36, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast;

2015
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom

2008
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
    International journal of oncology, 2008, Volume: 33, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cation

2008
Growth inhibitory effects of pegylated IFN-alpha2b and 5-fluorouracil in combination on renal cell carcinoma cell lines in vitro and in vivo.
    International journal of oncology, 2008, Volume: 33, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Transplantat

2008
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
    BJU international, 2009, Volume: 104, Issue:4

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C

2009
Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; C

2009
Acute aortic dissection during sorafenib-containing therapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aort

2010
Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:6

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Ren

2009
Chemo-immunotherapy in RCC: the end of a story.
    Lancet (London, England), 2010, Feb-20, Volume: 375, Issue:9715

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy, Combination; Fluorouracil; Humans; Immun

2010
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
    The Lancet. Oncology, 2010, Volume: 11, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Ce

2010
Spheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cells.
    Cancer letters, 2010, Dec-28, Volume: 299, Issue:2

    Topics: Animals; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Adhesion; Cell C

2010
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine;

2011
Combined immunochemotherapy in selected patients with metastatic renal cell carcinoma: HLA class II genotype can help to predict response to therapy.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2011, Volume: 34, Issue:2

    Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Comb

2011
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
    BJU international, 2011, Volume: 107, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
    BJU international, 2011, Volume: 107, Issue:5

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2011
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:6

    Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Com

2011
Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
    Molecular carcinogenesis, 2011, Volume: 50, Issue:10

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumo

2011
Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma.
    World journal of urology, 2013, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorodeoxygluc

2013
The expression and role of protein kinase C (PKC) epsilon in clear cell renal cell carcinoma.
    Journal of experimental & clinical cancer research : CR, 2011, Sep-28, Volume: 30

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcin

2011
Investigating cellular responses to novel chemotherapeutics in renal cell carcinoma using SR-FTIR spectroscopy.
    The Analyst, 2012, Oct-21, Volume: 137, Issue:20

    Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Fluorouracil; Humans; Principal Component An

2012
HER2 blockade in metastatic collecting duct carcinoma (CDC) of the kidney: a case report.
    Onkologie, 2012, Volume: 35, Issue:12

    Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2012
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil.
    European urology, 2003, Volume: 43, Issue:1

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Dihydrouracil Dehydrogenase (NADP); Drug Scr

2003
Significance of thymidylate synthase activity in renal cell carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, T

2003
Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Dihydrouraci

2003
Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysis.
    Cancer biotherapy & radiopharmaceuticals, 2003, Volume: 18, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; C

2003
Significance of orotate phosphoribosyltransferase activity in renal cell carcinoma.
    The Journal of urology, 2004, Volume: 171, Issue:2 Pt 1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Drug Screeni

2004
Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine.
    International journal of oncology, 2004, Volume: 24, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Buthionine

2004
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
    Der Urologe. Ausg. A, 2004, Volume: 43 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials

2004
[Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    Der Urologe. Ausg. A, 2004, Volume: 43, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Sur

2004
[First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Der Urologe. Ausg. A, 2004, Volume: 43, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorouracil; Germany

2004
Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2004, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Dose-Response Relati

2004
Long-term treatment of metastatic renal-cell carcinoma with fluorouracil.
    The Lancet. Oncology, 2004, Volume: 5, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Disease-Free Survival; Female; Fluorou

2004
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.
    Urologia internationalis, 2004, Volume: 73, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce

2004
Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
    Internal medicine journal, 2005, Volume: 35, Issue:1

    Topics: Administration, Cutaneous; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc

2005
Immunochemotherapy of metastatic renal cell carcinoma: report of 28 cases.
    Chinese medical journal, 2005, Jan-20, Volume: 118, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour

2005
Comparative analysis of caspase activation and apoptosis in renal tubular epithelial cells and renal cell carcinomas.
    Nephron. Experimental nephrology, 2005, Volume: 99, Issue:4

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Caspase 2;

2005
Adenovirus-mediated interleukin-12 gene transfer combined with cytosine deaminase followed by 5-fluorocytosine treatment exerts potent antitumor activity in Renca tumor-bearing mice.
    BMC cancer, 2005, May-24, Volume: 5

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line; C

2005
Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.
    Cancer biotherapy & radiopharmaceuticals, 2005, Volume: 20, Issue:4

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Disease-Free Survival; Female;

2005
Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma.
    Critical reviews in oncology/hematology, 2005, Volume: 55, Issue:3

    Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols;

2005
Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
    Urology, 2005, Volume: 66, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disea

2005
Metastatectomy prior to immunochemotherapy for metastatic renal cell carcinoma.
    Urologia internationalis, 2006, Volume: 76, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluoro

2006
Solitary metastasis in a nasal fossa as the first manifestation of a renal carcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carc

2006
Gene therapy with TRAIL against renal cell carcinoma.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:9

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Line, Tumor; Combined Modality

2006
Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon alpha and 5-fluorouracil.
    European urology, 2007, Volume: 51, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modalit

2007
Renal cell carcinoma in children: experience of a single center.
    Nephron. Clinical practice, 2007, Volume: 105, Issue:2

    Topics: Adolescent; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Car

2007
Synergy of interferon-alpha and 5-fluorouracil in human renal cell carcinoma requires p53 activity.
    European urology, 2007, Volume: 52, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Fluorouraci

2007
Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel.
    Urology, 2007, Volume: 69, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Caspases; Deoxycytidine; Drug Synergism; Flow C

2007
Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma.
    International journal of cancer, 2007, Nov-01, Volume: 121, Issue:9

    Topics: Aminoquinolines; Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Enzyme Activation; F

2007
[Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].
    Der Urologe. Ausg. A, 2007, Volume: 46, Issue:10

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, R

2007
Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2007, Volume: 30, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Comb

2007
Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival.
    Journal of Korean medical science, 2007, Volume: 22 Suppl

    Topics: Adult; Aged; Carcinoma, Renal Cell; Eosinophils; Female; Fluorouracil; Humans; Immunotherapy; Interf

2007
Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice.
    International journal of cancer, 2008, Jun-15, Volume: 122, Issue:12

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; CD4-Positive T-Lympho

2008
[Chemotherapy of renal cell carcinoma. 3. Single-agent therapy with FT-207 or vinblastine].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1984, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Huma

1984
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    The Journal of urology, 1996, Volume: 155, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Case-Control Studies; Combined Modality Therapy; Drug

1996
Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma.
    American journal of clinical oncology, 1995, Volume: 18, Issue:4

    Topics: Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon Type I; Interleukin-2; Kidney Neoplasms; Mal

1995
Interferon-alpha-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil.
    Cancer letters, 1995, Aug-01, Volume: 94, Issue:2

    Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Fl

1995
Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinoma.
    Cancer biotherapy, 1995,Spring, Volume: 10, Issue:1

    Topics: Adult; Aged; Ambulatory Care; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorouracil

1995
5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle.
    Cancer letters, 1993, Nov-30, Volume: 75, Issue:1

    Topics: Antigens, Differentiation, T-Lymphocyte; Carcinoma, Renal Cell; CD2 Antigens; Cell Adhesion; Cell Ad

1993
Renal cell cancer: is there long-term survival advantage from cytokine treatment?
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:9

    Topics: Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neop

1994
[Current status of chemotherapy for renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney

1994
[Immunotherapy of renal cell carcinoma from an urological viewpoint].
    Krankenpflege Journal, 1993, Volume: 31, Issue:9

    Topics: Carcinoma, Renal Cell; Female; Fluorouracil; Humans; Immunotherapy, Active; Interferon-alpha; Interl

1993
[Immunotherapy in metastatic cancer of the kidney].
    Presse medicale (Paris, France : 1983), 1995, Oct-28, Volume: 24, Issue:32

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Synergism; Drug

1995
Carpal tunnel syndrome associated with interleukin-2 therapy.
    Cancer, 1996, Mar-15, Volume: 77, Issue:6

    Topics: Adult; Carcinoma, Renal Cell; Carpal Tunnel Syndrome; Drug Therapy, Combination; Female; Fluorouraci

1996
[Three cases of lung metastases of renal cell carcinoma treated with a combination of interferon-alpha, 5-fluorouracil and leucovorin].
    Hinyokika kiyo. Acta urologica Japonica, 1996, Volume: 42, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; I

1996
Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.
    Urological research, 1996, Volume: 24, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Combined Modality Therapy; Drug

1996
[Immunochemotherapy of metastatic renal cell carcinoma with interleukin 2, interferon-alpha and 5-fluorouracil].
    Der Urologe. Ausg. A, 1997, Volume: 36, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Chemothe

1997
Biochemical modulation of 5-fluorouracil with murine interferon-alpha/beta against murine renal cell carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 1997, Volume: 4, Issue:2

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1997
Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines.
    British journal of cancer, 1997, Volume: 75, Issue:12

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

1997
IL-6 is a survival prognostic factor in renal cell carcinoma.
    Immunology letters, 1997, Volume: 58, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Biopterins; C-Reactive Protein; Carcinoma,

1997
Hyperplasia of axillary nodes in patients undergoing immunotherapy.
    AJR. American journal of roentgenology, 1997, Volume: 169, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma, Renal Cell; Fluorouracil; Humans;

1997
Enhancement of 5-fluorouracil cytotoxicity by folinic acid in different cell-lines of human renal cell carcinoma.
    European journal of medical research, 1996, Apr-18, Volume: 1, Issue:7

    Topics: Carcinoma, Renal Cell; Cell Division; Cell Survival; Drug Synergism; Fluorouracil; Humans; Kidney Ne

1996
[Outpatient chemotherapy with continuous intravenous infusion for patients with recurrent renal cell carcinoma or advanced prostate carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24 Suppl 4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell;

1997
[Immunotherapeutic treatment for metastatic renal carcinoma].
    Actas urologicas espanolas, 1998, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Fluorour

1998
[The correlation between thymidine phosphorylase activity of renal cancer cells and the chemosensitivity to 5-FU and 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:11

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Screening Assays

1998
Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients.
    British journal of cancer, 1999, Volume: 79, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

1999
Results of immunochemotherapy with interleukin-2, interferon-alpha2 and 5-fluorouracil in the treatment of metastatic renal cell cancer.
    European urology, 1999, Volume: 35, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Fluorouracil; Follo

1999
Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine.
    The Journal of urology, 1999, Volume: 162, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arachnoid; Carcinom

1999
Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase.
    Cancer chemotherapy and pharmacology, 1999, Volume: 44, Issue:2

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon-alpha; Kidn

1999
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:8

    Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel

1999
Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; C

1999
Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin.
    Cancer research, 2000, Jun-01, Volume: 60, Issue:11

    Topics: Acridine Orange; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents

2000
Antitumoral effect of a nonviral interleukin-2 gene therapy is enhanced by combination with 5-fluorouracil.
    Cancer gene therapy, 2000, Volume: 7, Issue:8

    Topics: Animals; Carcinoma, Renal Cell; Combined Modality Therapy; DNA, Complementary; Female; Fluorouracil;

2000
Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1

    Topics: Adenocarcinoma, Clear Cell; Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Com

2000
Enhancement of sensitivity to capecitabine in human renal carcinoma cells transfected with thymidine phosphorylase cDNA.
    International journal of cancer, 2001, May-01, Volume: 92, Issue:3

    Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Cell Survival; Deoxyc

2001
Activation of caspase-3 in renal cell carcinoma cells by anthracyclines or 5-fluorouracil.
    International journal of oncology, 2001, Volume: 19, Issue:1

    Topics: Amino Acid Chloromethyl Ketones; Antibiotics, Antineoplastic; Apoptosis; Carcinoma, Renal Cell; Casp

2001
Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:1

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosi

2002
HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
    Cancer biotherapy & radiopharmaceuticals, 2001, Volume: 16, Issue:5

    Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Renal C

2001
Characterization of the antitumor activities of IFN-alpha8 on renal cell carcinoma cells in vitro.
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2001, Volume: 21, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Division; DNA, Neoplasm; D

2001
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
    Angiogenesis, 2001, Volume: 4, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc

2001
Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma.
    Cancer letters, 2002, Sep-08, Volume: 183, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Chalcone; Chalcones; Dose-Response Relationsh

2002
Thymidine phosphorylase activity in renal cell carcinoma: relationship between histological parameters and chemosensitivity to fluorouracil-related drugs.
    Urological research, 2002, Volume: 30, Issue:2

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Floxuridine; Fluorouracil; Humans; Kidney; K

2002
Secretion of autocrine growth-promoting activity by renal-carcinoma cells treated with 5-fluorouracil.
    International journal of cancer, 1992, Aug-19, Volume: 52, Issue:1

    Topics: 3T3 Cells; Animals; Carcinoma, Renal Cell; DNA, Neoplasm; Fluorouracil; Growth Substances; Humans; K

1992
[Combined effects of alpha-interferon and anticancer drugs against renal cell carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:12

    Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma, Renal Cell; Combined Modality Therapy; Doxorub

1990
Concentration of 5-fluorouracil in renal cells from cancer patients administered a mixture of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil.
    International journal of clinical pharmacology research, 1991, Volume: 11, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney;

1991
[Combination chemotherapy of human renal cell carcinoma in athymic nude mice with human lymphoblastoid interferon (HLBI) and UFT, 5-Fu].
    Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Th

1990
[Antitumor activity of UFT against murine renal cell carcinoma: a study on the suppression tumor metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Screening Assay

1990
Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Evaluation;

1989
[A case of renal cell carcinoma with lung metastases successfully treated by interferon-beta].
    Hinyokika kiyo. Acta urologica Japonica, 1989, Volume: 35, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Fluorouracil; Humans; Interferon Type I; Kidney Neopla

1989
[Synchronous double cancers in the ovary and kidney--a case report].
    Gan no rinsho. Japan journal of cancer clinics, 1988, Volume: 34, Issue:14

    Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Com

1988
[5-FU concentration in blood and tissue of patients with renal cell carcinoma after administration of UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney

1985